Kick-start for metabolomics in liver disease

doi:10.4254/wjh.v16.i9.1206

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1201)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

701

Sum=736

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

109

Download

158

Sum=267

Publishing Process of This Article

Item

Count

Browse

Download

Sum=144

Sep 27, 2024 (publication date) through Feb 8, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Hepatol. Sep 27, 2024; 16(9): 1206-1210
Published online Sep 27, 2024. doi: 10.4254/wjh.v16.i9.1206

Kick-start for metabolomics in liver disease

Armando Guerra-Ruiz

Armando Guerra-Ruiz, Laboratory Medicine, University Hospital Marques de Valdecilla, Santander 39008, Cantabria, Spain

Armando Guerra-Ruiz, Commission on Biochemical Assessment of Liver Disease, Spanish Society of Clinical Chemistry (SEQC-ML), Barcelona 08025, Catalonia, Spain

Armando Guerra-Ruiz, Digestive Diseases, Valdecilla Research Institute (IDIVAL), Santander 39011, Cantabria, Spain

Author contributions: As the sole author, Guerra-Ruiz A was responsible for all aspects of the work, including conception, design, research, writing, and finalization of the manuscript. No external contributions or assistance were involved in the preparation of this editorial.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Armando Guerra-Ruiz, PhD, Consultant Physician-Scientist, Laboratory Medicine, University Hospital Marques de Valdecilla, Avda Valdecilla s/n, Santander 39008, Cantabria, Spain. r-gruiz@hotmail.com

Received: May 18, 2024
Revised: July 12, 2024
Accepted: July 17, 2024
Published online: September 27, 2024
Processing time: 128 Days and 9.4 Hours

Core Tip

Core Tip: This editorial explores the transformative potential of metabolomics in liver disease research and management. Highlighting four key studies, we explore how metabolomics aids in biomarker discovery, reveals altered biochemical pathways, supports personalized medicine, and elucidates disease mechanisms. By integrating metabolomics in clinical practice, we can enhance early diagnosis, optimize treatment strategies, and develop targeted therapies, ultimately improving patient outcomes. This comprehensive approach underscores the versatility and importance of metabolomics in advancing precision medicine for liver diseases.